Multiomics and digital monitoring during lifestyle changes reveal independent dimensions of human biology and health.
P4 medicine
lifestyle changes
multiomics data integration
personalized medicine
precision health
precision medicine
systems medicine
Journal
Cell systems
ISSN: 2405-4720
Titre abrégé: Cell Syst
Pays: United States
ID NLM: 101656080
Informations de publication
Date de publication:
16 03 2022
16 03 2022
Historique:
received:
11
02
2021
revised:
15
09
2021
accepted:
09
11
2021
pubmed:
3
12
2021
medline:
20
4
2022
entrez:
2
12
2021
Statut:
ppublish
Résumé
We explored opportunities for personalized and predictive health care by collecting serial clinical measurements, health surveys, genomics, proteomics, autoantibodies, metabolomics, and gut microbiome data from 96 individuals who participated in a data-driven health coaching program over a 16-month period with continuous digital monitoring of activity and sleep. We generated a resource of >20,000 biological samples from this study and a compendium of >53 million primary data points for 558,032 distinct features. Multiomics factor analysis revealed distinct and independent molecular factors linked to obesity, diabetes, liver function, cardiovascular disease, inflammation, immunity, exercise, diet, and hormonal effects. For example, ethinyl estradiol, a common oral contraceptive, produced characteristic molecular and physiological effects, including increased levels of inflammation and impact on thyroid, cortisol levels, and pulse, that were distinct from other sources of variability observed in our study. In total, this work illustrates the value of combining deep molecular and digital monitoring of human health. A record of this paper's transparent peer review process is included in the supplemental information.
Identifiants
pubmed: 34856119
pii: S2405-4712(21)00451-8
doi: 10.1016/j.cels.2021.11.001
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-255.e7Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests O.K. received research funding from Vinnova for collaboration between Astra Zeneca, Takeda, Pelago, and Labcyte. O.K. is also a board member and a co-founder of Medisapiens and Sartar Therapeutics and has received a royalty on patents licensed by Vysis-Abbot. R.S. is currently employed at Crown CRO.